Link to: ERA4TB
ERA4TB
- 32 participants
- > 207 M€ budget
- 6 years. Started 1 Jan 2020
Development of anti-TB drug combinations
Link to: RespiriNTM
RespiriNTM
- 9 participants
- > 8 M€ budget
- 6 years. Started 1 May 2019
Novel assets for non-tuberculous mycobacteria
Link to: RespiriTB
RespiriTB
- 9 participants
- > 9.9 M€ budget
- 6 years. Started 1 May 2019
New assets for multidrug-resistant tuberculosis
Link to: TRIC-TB
TRIC-TB
- 2 participants
- > 8.3 M€ budget
- 4 years. Started 1 May 2019
Define a new place for Ethionamide in 1st-line TB treatments
UNITE4TB
- 29 participants
- 185 M€ budget
- 7 years. Started 1 June 2021
Accelerate and improve clinical trials of combinations of existing and new drugs against TB